INKT
MiNK Therapeutics Accelerates Innovation with Impressive Q1 2026 Milestones
At its recent Q1 2026 conference call, MiNK Therapeutics unveiled an impressive array of achievements that solidify its position as a leader in the field of off-the-shelf invariant natural killer T (iNKT) cell therapies. During the call, Dr. Jennifer Buell, President and Chief Executive Officer, highlighted the company's